Moreover, pharmacological treatments, such as metformin or GLP-1 receptor agonists, have demonstrated efficacy in managing obesity-related metabolic dysfunction and should be considered when lifestyle interventions alone are insufficient. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.